(ANGO) AngioDynamics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ANGO) AngioDynamics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This AngioDynamics, Inc. BCG Matrix helps you assess how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before purchasing. Buy the full version to get the complete ready-to-use report.
Stars
NanoKnife
NanoKnife is AngioDynamics, Inc.'s irreversible electroporation platform for soft-tissue ablation in oncology, so it fits the fast-growing minimally invasive cancer-treatment space. AngioDynamics reported FY2025 net sales of about $306 million, and NanoKnife remains one of its clearest growth levers. If adoption keeps rising, it is the strongest Star candidate in the portfolio.
Solero
Solero fits AngioDynamics, Inc. as a Star because its microwave and radiofrequency systems target solid tumor ablation, where image-guided oncology procedures still see steady demand. Clinical use is still widening, and each case can create recurring procedural volume for hospitals and interventional teams. In a growing niche, Solero has room to scale as ablation shifts toward less invasive cancer care.
Auryon
Auryon fits "Stars" in AngioDynamics, Inc.'s BCG Matrix because it targets peripheral atherectomy in a PAD market that still drives a high procedure load. PAD affects about 230 million adults worldwide, so demand is real, not niche. If AngioDynamics keeps gaining share in endovascular therapies, Auryon can stay a growth engine.
AlphaVac
AlphaVac fits the Stars side of AngioDynamics, Inc. BCG Matrix because it targets mechanical thrombectomy and clot removal, both tied to a fast-growing thrombus management market. In fiscal 2025, AngioDynamics reported net sales of about $300 million, so AlphaVac still needs steady clinical adoption and sales support to scale faster.
Its value comes from use in high-need interventional cases, where faster clot removal can matter. The franchise can stay a Star only if physicians keep adopting it and AngioDynamics keeps backing training, data, and commercial reach.
- Mechanical thrombectomy drives growth
- Thrombus care stays a high-demand niche
- FY2025 sales were about $300 million
- Adoption and sales support still matter
Endovascular therapies
Endovascular therapies are AngioDynamics, Inc.'s clearest growth engine outside oncology ablation, led by thrombus management, atherectomy, and core peripheral products. These are procedure-driven categories, so demand tracks case volumes and new clinical adoption more than one-off purchases. Ongoing device upgrades and broader use in vascular labs keep this franchise in the "Star" zone.
- Thrombus management drives recurring procedure use
- Atherectomy benefits from new technique adoption
- Core peripheral products widen installed reach
- Innovation supports share in active markets
AngioDynamics’ Star Products Are Driving Growth
NanoKnife, Solero, Auryon, and AlphaVac are AngioDynamics, Inc.'s clearest Stars because they sit in growing, procedure-driven markets and support the company’s FY2025 net sales of about $306 million. NanoKnife and Solero lead in oncology ablation, while Auryon and AlphaVac tap high-need vascular care. The key test is faster physician adoption.
| Star product | Market signal | FY2025 note |
|---|---|---|
| NanoKnife | Oncology ablation | Growth lever |
| Auryon | PAD treatment | Procedure demand |
| AlphaVac | Thrombectomy | Needs scale |
What is included in the product
Detailed Word Document
AngioDynamics BCG Matrix maps its businesses into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page AngioDynamics BCG Matrix to quickly spot winners, losers, and capital priorities.
Reference Sources
Shows the source trail behind AngioDynamics data, making the analysis more credible and easier to use in decisions.
Cash Cows
BioFlo PICC
BioFlo PICC is a mature vascular access brand, so it fits Cash Cows in AngioDynamics, Inc.’s BCG Matrix. PICCs are used for weeks to months in hospitals and infusion centers, and their established clinical role supports steady repeat demand and stable cash flow.
BioFlo Midline
In FY2025, AngioDynamics generated about $303 million in net sales, and BioFlo Midline sits in a mature inpatient category where routine vascular access demand stays steady.
Midline catheters are standard hospital products, so utilization is recurring and less tied to new market buildout.
That makes BioFlo Midline a classic cash cow: limited growth spend, stable volume, and reliable cash generation.
BioFlo Port
BioFlo Port is a mature implantable port in AngioDynamics, Inc.’s portfolio, used for chemotherapy and other repeat infusions. As a 2025-style Cash Cow, it sits in an established category that usually brings steady replacement demand, stable margins, and dependable cash flow. AngioDynamics, Inc.’s fiscal 2025 filings still showed the value of installed-base revenue in this franchise.
Vortex
Vortex is an implantable port brand in AngioDynamics, Inc.'s vascular access line, and ports are a mature hospital category with steady replacement demand. That makes Vortex a cash-cow asset, not a heavy growth bet. AngioDynamics reported fiscal 2025 net sales of $304.9 million and gross margin of 52.4%, which supports cash generation over aggressive expansion.
- Mature, recurring hospital use
- Low-growth, cash-focused fit
- Supports portfolio profitability
DuraMax
DuraMax sits in catheter-based vascular access, where hospitals rely on stable, repeat-use workflows. That makes it fit the BCG Cash Cow slot: low-growth, but able to keep generating cash because the clinical need is steady and the product is already embedded in routine care.
- Catheter-based vascular access
- Stable hospital workflow use
- Low growth, cash-rich profile
For AngioDynamics, Inc., DuraMax is more about harvesting margins than chasing rapid category growth.
AngioDynamics’ Cash Cows Deliver Steady, Margin-Backed Cash Flow
BioFlo PICC, BioFlo Midline, BioFlo Port, Vortex, and DuraMax are Cash Cows for AngioDynamics, Inc. because they sit in mature vascular access niches with recurring hospital use and limited growth spend. FY2025 net sales were about $303 million to $304.9 million, and gross margin was 52.4%, which supports steady cash generation.
| Product | BCG fit | Why |
|---|---|---|
| BioFlo PICC | Cash Cow | Repeat demand |
| BioFlo Midline | Cash Cow | Routine inpatient use |
| BioFlo Port | Cash Cow | Installed base revenue |
| Vortex | Cash Cow | Stable replacement demand |
| DuraMax | Cash Cow | Harves t margins |
What You See Is What You Get
AngioDynamics, Inc. Reference Sources
You’re previewing the actual AngioDynamics, Inc. BCG Matrix document you’ll receive after purchase. The file is fully formatted and ready to use, with no demo pages or hidden content. What you see here is the same professional report delivered instantly after checkout. It’s designed for quick review, printing, or sharing with your team.
Dogs
Angiographic catheters
AngioDynamics, Inc.’s angiographic catheters fit the Dogs box: they are standard interventional-lab tools with low differentiation, so price pressure stays intense. In a crowded catheter market that supports only modest growth, these products usually add little operating leverage. That is why they tend to trail higher-value lines in margin and return on capital.
Guidewires
Guidewires are foundational interventional accessories, but they compete in a crowded field dominated by larger medtech suppliers. For AngioDynamics, Inc., this fits a Dogs profile: low growth, low relative share, and limited pricing power, which is why the line usually acts as a cash drain rather than a growth driver.
Percutaneous drainage catheters
Percutaneous drainage catheters sit in routine image-guided care, so demand is steady but not fast-growing. In AngioDynamics, Inc.'s BCG Matrix, that profile fits a weak "Dog" because the market is fragmented and pricing is commodity-like, with little scope for margin expansion. This makes it a low-priority line versus faster-growth, higher-return categories.
Coaxial micro-introducer kits
Coaxial micro-introducer kits are a necessary access tool in AngioDynamics, Inc.'s portfolio, but they usually stay a low-growth "Dog" because they support procedure setup more than they drive demand. AngioDynamics reported fiscal 2025 results at the company level, but it did not break out revenue for this kit line, which points to limited standalone scale. The line is more likely to be maintained for clinical completeness than pushed for major expansion.
- Useful, but not a growth engine.
- Supports access and placement.
- Likely kept, not aggressively expanded.
IsoLoc and Alatus
IsoLoc and Alatus address narrow positioning and packing needs, so they fit a Dog in AngioDynamics, Inc.’s BCG Matrix. AngioDynamics reported fiscal 2025 revenue near $307 million, and these products do not look like scale drivers versus its bigger med-tech focus. Small niche demand and slow category growth keep their cash potential limited.
- Niche use, not broad demand
- Small scale limits growth
- Best viewed as a Dog
AngioDynamics Dogs: Small, Slow, and Best Kept for Coverage
AngioDynamics, Inc.’s Dogs are low-share, low-growth lines with weak pricing power, so they add little profit lift. In fiscal 2025, company revenue was about $307 million, but these niche accessories did not show the scale needed to change the mix. They are usually kept for coverage and completeness, not expanded.
| Signal | Dogs fit |
|---|---|
| Growth | Low |
| Share | Small |
| Role | Maintain |
Question Marks
AlphaVac PE
AlphaVac PE sits in a growing pulmonary embolism market, and PE affects about 900,000 people a year in the U.S. AngioDynamics is still building broader share, so AlphaVac is a question mark, not a cash cow. It needs more investment and adoption to become a clear market leader.
Auryon CLI
Auryon CLI sits in a growing niche: critical limb ischemia and complex PAD still need better endovascular tools, so demand can rise with more physician adoption. In AngioDynamics, Inc. FY2025 results, the product still needs clear share gains and a larger installed base to move out of Question Mark territory. If adoption broadens, it can capture more of this high-need market, but today its growth is still not proven.
NanoKnife pancreas
NanoKnife pancreas fits the Question Mark box: pancreatic cancer still has about a 13% 5-year survival rate, so the unmet need is high. AngioDynamics, Inc. is chasing that need, but adoption is still limited and must broaden beyond early users. The clinical upside is real, yet FY2025 demand is still in build mode rather than at scale.
Solero liver tumors
Solero fits a growing liver tumor ablation market, and that demand supports its BCG Question Mark status. AngioDynamics reported FY2025 net sales of about $286 million, but Solero still needs sharper share gains before it can look like a Star.
- Growing liver ablation demand helps Solero.
- Market penetration still looks too thin.
- Share gains matter more than market growth.
BioSentry
BioSentry fits the Question Mark in AngioDynamics, Inc.'s BCG Matrix: it solves a real clinical need as a tract sealant, but the market is narrow and the product still has limited scale. That means growth can exist, but current share looks too small to call it a Star. BioSentry needs heavier adoption and sales pull before it can move out of this low-share, high-uncertainty box.
- Specialized procedural product
- Real clinical need, narrow market
- Growth possible, share still limited
AngioDynamics’ Growth Bets Are Still Unproven
AngioDynamics, Inc.’s Question Marks are still growth bets, not proven winners. In FY2025, the company reported about $286 million in net sales, while AlphaVac PE, Auryon CLI, NanoKnife pancreas, Solero, and BioSentry all needed more share and broader adoption.
| Product | FY2025 signal | BCG role |
|---|---|---|
| AlphaVac PE | Early share | Question Mark |
| Auryon CLI | Adoption building | Question Mark |
| NanoKnife pancreas | Limited uptake | Question Mark |
| Solero | Share still thin | Question Mark |
| BioSentry | Narrow market | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.